ClinicalTrials.gg
RecruitingNCT05433467CTMHUpdated Aug 13, 2025

CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection

An interventional study of CT-guided localization for micro hepatocellular carcinoma before surgical resection in Cirrhosis, Liver and Hepatocellular Carcinoma, sponsored by Northern Jiangsu People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Northern Jiangsu People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital — 8 open to participants now, 8 under way, none of them phase 3. Liver Cirrhosis · Northern Jiangsu People's Hospital.

Started
2022
with 5 others
No phase
5 of 11
4 open now
Registered
5th of 11
by date

Among the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, this one is one of 6 that started in 2022, is one of 5 with no phase, and was the 5th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

8 of the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, or all of them as a file.
02

Study summary

In this project, the preoperative anatomical location of micro hepatocellular carcinoma under the guidance of CT can provide guidance for accurate surgical resection. It may also shorten the operation time and reduce intraoperative bleeding.

Read the detailed description

General and basic information of the patients included in the study was collected. After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.

03

Conditions studied

  • Cirrhosis, Liver
  • Hepatocellular Carcinoma

Keywords

  • Cirrhosis
  • hepatocellular carcinoma
  • localization needle
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be at least 18 years old and give to participate in the study
  2. A preoperative (clinical, radiological, or histological) diagnosis of cirrhosis of the liver due to any cause.
  3. micro hepatocellular carcinoma (diameter less than 1cm).
  4. Preoperative CT plain scan could not find the lesion, and preoperative B-ultrasound could not find the lesion.
  5. Preoperative CT enhancement or MRI can detect the lesion.

Exclusion criteria

Exclusion Criteria:

  1. grade C
  2. Uncontrolled Hypertension
  3. Severe lung dysfunction
  4. Severe cardiac dysfunction
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    CT-guided localization for micro hepatocellular carcinoma before surgical resection

    fter preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.

    Procedure: CT-guided localization for micro hepatocellular carcinoma before surgical resection

Interventions

  • ProcedureCT-guided localization for micro hepatocellular carcinoma before surgical resection

    After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.

06

What researchers measure

Primary outcomes

  1. The position of the needle

    The distance (mm) of the needle to the edge of hepatocellular carcinoma

    Time frame: During operation

Secondary outcomes

  1. Operation time

    The length of operation time (min)

    Time frame: During operation

  2. Intraoperative bleeding

    The volume of intraoperative bleeding (ml)

    Time frame: During operation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Apr 2026, 47 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 47 months is above that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
May 1, 2022
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05433467
Lead sponsor
Northern Jiangsu People's Hospital
Responsible party
Guo-Qing Jiang (Clinical Professor, Northern Jiangsu People's Hospital) — Principal investigator
First posted
Jun 27, 2022
Start date
May 1, 2022
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Aug 13, 2025

Study contacts

Guo-Qing Jiang, MD
Contact
jgqing2003@hotmail.com
+8651487373382
Dou-Sheng Bai, MD
Contact
jgqing2003@hotmail.com
+8651487373382
Guo-Qing Jiang, MD
study chair · Clinical Medical College, Yangzhou University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion